BSE Live
Dec 10, 14:42Prev. Close
190.10
Open Price
189.95
Bid Price (Qty.)
187.50 (483)
Offer Price (Qty.)
187.75 (22)
NSE Live
Dec 10, 14:42Prev. Close
190.11
Open Price
189.61
Bid Price (Qty.)
187.61 (21)
Offer Price (Qty.)
187.75 (44)
| Key Financial Ratios of Marksans Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.93 | 1.07 | 0.30 | 0.28 | 1.75 | |
| Diluted EPS (Rs.) | 0.93 | 1.07 | 0.30 | 0.28 | 1.75 | |
| Cash EPS (Rs.) | 1.21 | 1.28 | 0.60 | 0.65 | 2.11 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 12.35 | 11.50 | 10.48 | 10.23 | 10.02 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 12.35 | 11.50 | 10.48 | 10.23 | 10.02 | |
| Dividend / Share(Rs.) | 0.10 | 0.05 | 0.05 | 0.05 | 0.12 | |
| Revenue from Operations/Share (Rs.) | 10.59 | 10.36 | 7.20 | 5.27 | 8.75 | |
| PBDIT/Share (Rs.) | 1.75 | 1.74 | 0.89 | 0.77 | 2.75 | |
| PBIT/Share (Rs.) | 1.47 | 1.53 | 0.59 | 0.40 | 2.39 | |
| PBT/Share (Rs.) | 1.29 | 1.37 | 0.41 | 0.29 | 2.24 | |
| Net Profit/Share (Rs.) | 0.93 | 1.07 | 0.30 | 0.28 | 1.75 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 16.53 | 16.80 | 12.41 | 14.56 | 31.43 | |
| PBIT Margin (%) | 13.84 | 14.75 | 8.25 | 7.61 | 27.31 | |
| PBT Margin (%) | 12.16 | 13.20 | 5.65 | 5.53 | 25.58 | |
| Net Profit Margin (%) | 8.74 | 10.28 | 4.21 | 5.34 | 19.96 | |
| Return on Networth / Equity (%) | 7.49 | 9.26 | 2.89 | 2.75 | 17.42 | |
| Return on Capital Employed (%) | 11.31 | 12.79 | 5.45 | 3.76 | 16.89 | |
| Return on Assets (%) | 6.31 | 7.12 | 2.22 | 2.11 | 13.38 | |
| Total Debt/Equity (X) | 0.00 | 0.16 | 0.15 | 0.17 | 0.10 | |
| Asset Turnover Ratio (%) | 72.26 | 69.30 | 52.87 | 39.54 | 67.04 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.52 | 2.21 | 2.09 | 1.98 | 1.84 | |
| Quick Ratio (X) | 2.44 | 1.64 | 1.71 | 1.71 | 1.44 | |
| Inventory Turnover Ratio (X) | 5.81 | 6.03 | 6.97 | 7.38 | 8.19 | |
| Dividend Payout Ratio (NP) (%) | 6.50 | 4.69 | 19.82 | 51.20 | 8.09 | |
| Dividend Payout Ratio (CP) (%) | 4.97 | 3.91 | 9.98 | 22.26 | 6.71 | |
| Earnings Retention Ratio (%) | 93.50 | 95.31 | 80.18 | 48.80 | 91.91 | |
| Cash Earnings Retention Ratio (%) | 95.03 | 96.09 | 90.02 | 77.74 | 93.29 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 565.59 | 1,102.67 | 1,371.07 | 2,011.58 | 1,941.02 | |
| EV/Net Operating Revenue (X) | 1.30 | 2.60 | 4.65 | 9.32 | 5.42 | |
| EV/EBITDA (X) | 7.89 | 15.47 | 37.49 | 63.98 | 17.24 | |
| MarketCap/Net Operating Revenue (X) | 1.31 | 2.40 | 4.40 | 8.94 | 5.28 | |
| Retention Ratios (%) | 93.49 | 95.30 | 80.17 | 48.79 | 91.90 | |
| Price/BV (X) | 1.13 | 2.16 | 3.02 | 4.61 | 4.61 | |
| Price/Net Operating Revenue | 1.31 | 2.40 | 4.40 | 8.94 | 5.28 | |
| Earnings Yield | 0.07 | 0.04 | 0.01 | 0.01 | 0.04 |
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
09.09.2025
Marksans Pharma Standalone June 2025 Net Sales at Rs 319.73 crore, up 25.62% Y-o-Y
20.05.2025
Marksans Pharma Consolidated March 2025 Net Sales at Rs 708.46 crore, up 26.51% Y-o-Y